Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Aug 09, 2024 10:53am
Management’s Priority
Well a week ago we were greeted with more material news regarding the upcoming Pontiac trial, as usual it had zero impact on share price, market cap or daily volume. We are at a stage where future
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Aug 07, 2024 9:34am
Communication
There are many things out of the control of management, such as final ethics approvals from Canadian sites participating in the AKI Phase 2 Study or news flowing from the new Pontiac Trial announced.
...more
(69)
•••
PeptidePete
X
View Profile
View Bullboard History
Post by
PeptidePete
on Aug 05, 2024 12:34pm
Great Management - Grant Saves Shareholder Dilution Again!!
The recent PONTIAC trial grant saves shareholders 1,268,000 shares in dilution. Since 2018 the company has only performed 4 financings, all Non Brokered with No Warrants.
...more
(69)
•••
PeptidePete
X
View Profile
View Bullboard History
Post by
PeptidePete
on Aug 05, 2024 12:12pm
Another Free Phase II Trial
The PONTIAC clinical team of investigators was awarded $1,500,000 by the CHIHR and $400,000 from ACT, both of these grants will be used by the clinical team to conduct the pontiac trial.
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Aug 02, 2024 10:00am
Arch is the real Deal
And they have the science and the data to prove it! The Canadian government just doesn’t hand out grants to anyone. You don’t get asked to participate in a Pontiac trial unless you
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 02, 2024 7:20am
New Press Release - Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissueArch continues to perform a...
read article.
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Aug 01, 2024 9:41am
Redemption Time
Redemption Time Okay time for Management to step up here. Last weekend Peptide Pete took the time to post all the material milestones that Arch has accomplished over the past few
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 31, 2024 7:20pm
House of Pain
Management’s decision to do a desperate raise at the wrong time has put us in the house of pain. Down 5% today on higher than average daily volume. This private placement
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 30, 2024 6:35pm
Apologies
My apologies for not spell checking. Posting from a phone. My last post revised below: Management drops the ball I am still dumbfounded regarding the $600,000 private
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 30, 2024 4:47pm
New Press Release - Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement disclosed in a press release July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400...
read article.
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 30, 2024 3:05pm
Management drops the ball
I am still dumbfounded regarding the $600,000 private place announced last night at $1.50 This should not come as a surprise regarding a private placement to raise funds. The financials and the
...more
(254)
•••
Viking2233
X
View Profile
View Bullboard History
Post by
Viking2233
on Jul 29, 2024 5:53pm
Private Placement
Wow, what can I say. Raising $600K now when share price is at $1.50. The share price is down 30% in the past year, this could have and should have been done at a higher valuation. They did a similar
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 29, 2024 4:52pm
New Press Release - Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross...
read article.
(6)
•••
Renal22
X
View Profile
View Bullboard History
Comment by
Renal22
on Jul 28, 2024 10:33pm
RE:GMP Glass vial stage for Cilastatin
RiverandPeteFolk
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >